Hematopoietic Stem Cells Transplantation Market Size & Share, by Transplant Type (Allogeneic, Autologous); Application (Peripheral Blood Stem Cell Transplant, Bone Marrow Transplant, Cord Blood Transplant); Disease Indication (Lymphoproliferative Disorders, Leukemia, Non-Malignant Disorders); End-user (Hospitals, Specialty Centers) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 3937
  • Published Date: Nov 01, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024 - 2036

Hematopoietic Stem Cells Transplantation Market size is poised to reach USD 9 Billion by the end of 2036, growing at a CAGR of 12% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of hematopoietic stem cells transplantation was USD 3 Billion. The reason behind the growth is impelled by the rising prevalence of leukemia. Hematopoietic stem cell transplantation can be used to treat certain cancers, including leukemia, as stem cells aid in immune system restoration and the stimulation of new bone marrow development that may benefit patients to regenerate healthy bone marrow. In 2020, there were more than 474,510 new cases of leukemia reported globally.

The growing advancements in stem cell transplantation technology are believed to fuel the market growth. For instance, in February 2023, Lund University in Sweden discovered that stem cells have shown promise in treating the inflammation that underlies heart failure as it was found that patients receiving the treatment had more than 55% lower risk of heart attack or stroke, and the benefits rose to over 70% in patients with high inflammation since the treatment may decrease plaque instability.

Hematopoietic Stem Cells Transplantation Market
Get more information on this report: Request Free Sample PDF

Hematopoietic Stem Cells Transplantation Sector: Growth Drivers and Challenges

Growth Drivers

  • Rising Elderly Population – Hematopoietic cell transplant (HCT) is increasingly being referred by physicians to older adults for the treatment of malignancies since age is no longer seen as a complete barrier to hematopoietic stem cell transplantation (HSCT). As per the World Health Organization, the worldwide geriatric population was over 524 million in 2010 and this number is expected to cross 2 billion by 2050.
  • Growing Incidence of Lymphoma- Stem cell transplantation is frequently used to treat blood malignancies such as Hodgkin lymphoma and non-Hodgkin lymphoma by replacing damaged bone marrow cells with healthy stem cells.
  • Increasing Prevalence of Sickle Cell Disorders- The sole treatment for individuals with sickle cell disease (SCD) is hematopoietic stem cell transplantation (HSCT) since it entails transferring healthy cells from a sibling or sister who qualifies to replace the aberrant stem cells that are present in the bone marrow.
  • Surging Research & Development Activities- For instance, in 2020, Gamida Cell announced that it had completed enrollment in the Phase 3 clinical trial of its hematopoietic stem cell product.


  • Adverse Effected Resulting From Hematopoietic Stem Cells Transplantation  - Numerous adverse effects of an HSCT transplant resemble those that are frequently experienced after receiving radiation and chemotherapy including greater risk of infection, relapse in illness, death from CMV infection, and graft-versus-host disease (GVHD) which may result from age, baseline performance condition, the source of the stem cell transplant, the kind and severity of the preparative regimen, and many other factors. Moreover, patients who had severe marrow fibrosis before transplantation may also experience graft failure which is frequently linked to a cancer recurrence as the leukemic cells may prevent the transplanted cells from growing.
  • High Cost of Hematopoietic Stem Cells Transplantation Treatment Owing to the Complexity of the Procedure
  • Limited Availability of Matched Donors As it Involves Intricate Tissue Typing and HLA Matching

Hematopoietic Stem Cells Transplantation Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~ USD 3 Billion

Forecast Year Market Size (2036)

~ USD 9 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Hematopoietic Stem Cells Transplantation Segmentation

Transplant Type (Allogeneic, Autologous)

The autologous segment is estimated to account for 58% share of the global hematopoietic stem cells transplantation market in the coming years owing to the rising prevalence of cancer. The incidence of cancer increases sharply with age, most likely because certain malignancies have accumulating risks that climb with age. The primary driver of the general increase in cancer risk is our advancing age, adoption of a Western lifestyle, poor eating practices, dairy products, processed foods, food additives, non-vegetarian diets, chemical pollution, constipation, and physical inactivity. This has significantly led to an increase in the demand for autologous hematopoietic stem cell transplantation as it is used to treat certain types of cancer.

An autologous stem cell transplant also known as autologous bone marrow transplant replaces malfunctioning bone marrow with healthy blood stem cells from within the body that are utilized for patients whose illnesses require heavy dosages of radiation and chemotherapy whereby the damaged bone marrow is partially restored with the use of an autologous stem cell transplant. According to estimates, there were more than 609,810 cancer deaths and over 1,957,310 new cancer cases in the US in 2023.

Application (Peripheral Blood Stem Cell Transplant, Bone Marrow Transplant, Cord Blood Transplant)

Hematopoietic stem cells transplantation market from the blood stem cell transplant segment is set to garner a notable share shortly. A blood stem cell transplant is a surgical technique that involves the transplantation of peripheral blood stem cells, cord blood, and bone marrow to introduce healthy blood-forming cells from a donor into the patient's circulation, where they start to proliferate and produce platelets, red blood cells, and white blood cells.

End-User (Hospitals, Specialty Centers)

The hospitals segment is anticipated to gain a robust market share of 54% during the forecast timeframe. The treatment for hematopoietic stem cell transplantation is usually done in hospitals as they offer a whole spectrum of transplant services and the availability of skilled medical professionals.

Our in-depth analysis of the global hematopoietic stem cells transplantation market includes the following segments:

          Transplant Type

  • Allogeneic
  •  Autologous


  • Peripheral Blood Stem Cell Transplant
  •  Bone Marrow Transplant
  •  Cord Blood Transplant

          Disease Indication

  • Lymphoproliferative Disorders
  • Leukemia
  • Non-Malignant Disorders


  • Hospitals
  •  Specialty Centers

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Hematopoietic Stem Cells Transplantation Industry - Regional Synopsis

North American Market Forecast

Hematopoietic stem cells transplantation market in North America is predicted to account for the largest share of 40% by 2036 impelled by the presence of major key players in the region. This has led to increasing mergers and acquisitions in the region which has led to the development of advanced hematopoietic stem cell transplantation treatment. For instance, in 2021, Avalon GloboCare Corp. acquired Hebei Senlang Biotechnology Co. Ltd. to create a strong pipeline that comprises over 14 universal, autologous, "off-the-shelf" CAR-T and CAR-γδT cell therapy candidates to enhance cutting-edge cell/gene engineering and exclusive cell expansion knowledge with exceptional therapeutic efficacy and safety profile.

APAC Market Statistics

The APAC hematopoietic stem cells transplantation market is estimated to be the second largest, during the forecast timeframe led by growing medical tourism. India is becoming a major destination for medical tourism, providing people from all over the world with high-quality healthcare at reasonable prices, and cutting-edge medical facilities. India has become a popular location for people undergoing stem cell transplants aided by the availability of cutting-edge facilities, skilled medical personnel, and cutting-edge technology that attracts medical tourists who may not be able to pay or obtain them in their native countries.

Research Nester
Hematopoietic Stem Cells Transplantation Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Hematopoietic Stem Cells Transplantation Landscape

    • Lonza Group Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Escape Therapeutics, Inc.
    • Regen BioPharma, Inc.
    • ThermoGenesis Holdings, Inc.
    • CSG-BIO Company, Inc. (CellSave)
    • CBR Systems, Inc.
    • Pluristem Inc.
    • Global Cord Blood Corporation
    • ViaCord, LLC
    • Cynata Therapeutics Limited

In the News

  • Lonza Group announced to increase the number of human stem cells it offers by supplying big batch sizes of CD34+ hematopoietic stem cells from human cord blood to expand cohorts for greater capacity and easier HLA-matched model development.
  • Regen BioPharma, Inc. Announced the introduction of a novel immunotherapy approach using chimeric antigen receptor (CAR) natural killer (NK), macrophage (M), and T cells (T) to overcome the challenges associated with T cell fatigue in existing strategies and enable these cell therapies to successfully target solid tumors.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 3937
  • Published Date: Nov 01, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising prevalence of leukemia and the growing advancements in stem cell transplantation technology are the major factors driving the growth of the market.

The market size of hematopoietic stem cells transplantation is anticipated to attain a CAGR of 12% over the forecast period, i.e., 2024 – 2036.

The major players in the market are Escape Therapeutics, Inc., Regen BioPharma, Inc., ThermoGenesis Holdings, Inc., CSG-BIO Company, Inc. (CellSave), CBR Systems, Inc., Pluristem Inc., Global Cord Blood Corporation, ViaCord, LLC, Cynata Therapeutics Limited, and others.

The autologous segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

Hematopoietic Stem Cells Transplantation Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying